Stockwinners Market Radar for July 10, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:24 EDT DocuSign exec sells $4.9M in common stock - In a regulatory filing, DocuSign disclosed that its Field Operations President Stephen Shute sold 100.3K shares of common stock on July 6th in a total transaction size of $4.9M.

21:18 EDT Terreno Realty reports Q2 occupancy of 97.8% vs. 97.9% last year - Terreno Realty announced its operating, investment and capital markets activity for the second quarter of 2023. As of June 30, 2023, Terreno Realty Corporation owned 257 buildings aggregating approximately 15.8 million square feet and 46 improved land parcels consisting of approximately 165.8 acres: The operating portfolio was 97.8% leased at June 30, 2023 to 566 tenants as compared to 98.1% at March 31, 2023 and 97.9% at June 30, 2022. Occupancy decreased during the second quarter primarily due to a 45,000 square foot short-term sale leaseback expiration at the Company's recently acquired Long Island City property. The property was subsequently leased with a September 1, 2023 commencement date; The same-store portfolio of approximately 13.2 million square feet was 98.4% leased at June 30, 2023 as compared to 98.5% at March 31, 2023 and 97.1% at June 30, 2022; The improved land portfolio of 46 parcels totaling approximately 165.8 acres was 96.3% leased at June 30, 2023 as compared to 98.9% at March 31, 2023 and 97.0% at June 30, 2022; Cash rents on new and renewed leases totaling approximately 0.8 million square feet and 3.0 acres of improved land commencing during the second quarter increased approximately 59.2% with a tenant retention ratio of 51.7% for the operating portfolio and 0.0% for the improved land portfolio. Cash rents on new and renewed leases totaling approximately 1.3 million square feet and 8.6 acres of improved land commencing during the six months ended June 30, 2023 increased approximately 64.3% with a tenant retention ratio of 52.9% for the operating portfolio and 0.0% for the improved land portfolio.

20:03 EDT Cathie Wood's ARK Investment bought 170K Adaptive Biotechnologies shares today

19:29 EDT VMware exec sells $2.45M in common stock - In a regulatory filing, VMware disclosed that its EVP Jean Brulard sold 17.2K shares of common stock on July 7th in a total transaction size of $2.45M.

17:42 EDT CA American Water relaxes water requirements for Monterey Peninsula customers - California American Water is updating the watering schedule for outdoor landscaping after the Monterey Peninsula Water Management District moved mandatory conservation levels from Stage 2 to Stage 1. "Conservation is always in season in Monterey and we have work to do to solve our water supply challenges," said Chris Cook, Central California Director of Operations. "Even though we were fortunate to have had a very wet winter, it's still crucial that all of us in our community continue to use water wisely." California American Water and MPWMD require customers in Monterey, Carmel, Seaside, Pacific Grove, Pebble Beach, Del Rey Oaks, Sand City and Carmel Valley to follow the two day per week watering schedule.

17:20 EDT Zscaler CFO sells $1.82M in common stock - In a regulatory filing, Zscaler disclosed that its CFO Remo Canessa sold 12.5K shares of common stock on July 10th in a total transaction size of $1.82M.

17:01 EDT InterCure board approves voluntary delisting from TSX - InterCure Ltd. announced that its board of directors has approved the voluntarily delisting of the company's common shares from the Toronto Stock Exchange. The Company has decided to delist from the TSX after concluding that maintaining the listing does not offer substantial benefits to the Company and its shareholders. The Shares are currently listed on the NASDAQ and the Tel Aviv Stock Exchange, in addition to them being listed on the TSX. After a careful review of the trading volume data relating to the Shares, the Board has concluded that the trading volume on the TSX in insufficient to justify the continued listing. The Issuer will, however, remain a "reporting issuer" under applicable Canadian securities laws and continue to provide regular comprehensive disclosure pursuant to National Instrument 71-102 - Continues Disclosure and Other Exemptions Relating to Foreign Issuers as a "SEC Foreign Issuer."

16:46 EDT Learn CW Investment plans to extend period to consummate initial business deal - Learn CW Investment Corporation, a special purpose acquisition company, announced that the company intends to further extend the period of time the company will have to consummate its initial business combination by an additional one month from July 13, 2023 to August 13, 2023, subject to the timely deposit of an aggregate of $115,000 into the company's trust account on or prior to July 13, 2023. This Extension is the fourth of up to six one-month extensions permitted under the company's governing documents.

16:45 EDT Gatos Silver reports Q2 silver production of 2.0M oz, down 13% from last year

16:35 EDT Ameresco announces battery energy storage asset contract with United Power - Ameresco announced the signing of a contract for a significant battery energy storage asset in partnership with United Power, an electric cooperative serving Colorado's northern Front Range. The groundbreaking asset installation entails a multiple site, 78.3 MW, 313.34 MWh battery storage system, spanning a 20-year agreement between Ameresco and United Power. By strategically locating battery arrays throughout United Power's service territory, this endeavor will empower the cooperative to balance its load effectively while seamlessly integrating renewable resources into their operations. "The use of batteries on our distribution network is essential to a resilient and responsive power system, and we are excited to be moving ahead with one of the most aggressive plans for such a system," stated Mark A. Gabriel, President and CEO of United Power. "These battery arrays will allow us to balance our power needs throughout the day and incorporate local renewables more efficiently." Ameresco will provide four 11.75 MW and four 7.84 MW battery arrays across eight different substation sites owned by United Power, encompassing Adams, Broomfield, and Weld counties. These batteries will empower the cooperative to store and dispatch power efficiently during periods of high consumption. By leveraging this state-of-the-art technology, United Power will optimize their energy resources, enhance their grid resilience, and ensure a reliable electricity supply for their customers.

16:32 EDT EXL names Vishal Chhibbar chief growth and strategy officer - EXL announced the appointment of Vishal Chhibbar as executive vice president and chief growth and strategy officer. He will report to Rohit Kapoor, vice chairman and chief executive officer of EXL and will be an executive committee member. The appointment marks Chhibbar's return to EXL after serving as the company's chief financial officer from 2009 to 2019, where he instituted some of EXL's foundational growth strategies. In his new role, Chhibbar will draw on his leadership experience, financial expertise, and knowledge of EXL's business to spearhead EXL's growth, overseeing areas such as strategy, marketing, sales governance, mergers and acquisitions and partnerships. "Vishal brings that unique combination of deep expertise grounded in the fundamentals with the vision and creativity to see the next big opportunity and seize it," said Kapoor. "As our business continues to grow at a rapid pace, driven increasingly by our work leading enterprise digital transformation initiatives and large-scale AI deployments, Vishal's practical insights and keen instincts will be a tremendously valuable asset. I'm thrilled to have him back on the team."

16:32 EDT Casella Waste, Waga Energy sign pact to develop renewable natural gas - Casella Waste Systems and Waga Energy announced the signing of a commercial agreement on July 10, 2023 to develop renewable natural gas facilities at three Casella landfills. As part of the commercial agreement, Waga Energy will deploy the capital required to fully fund construction of the projects and will own and operate the RNG infrastructure. Casella and Waga Energy will share in the revenue generated from the RNG facilities once operational. Commercial operations are expected to start in approximately 24 months given the timeline for permitting and construction. The initial production across these three sites is expected to total approximately 1,300,000 MMBtu per year of RNG. Casella will receive from Waga Energy a royalty stream to supply landfill gas to the RNG facilities and the projects may be entitled to investment tax credits as part of the Inflation Reduction Act.

16:31 EDT Better Therapeutics receives FDA authorization for AspyreRx - Better Therapeutics announced that the FDA authorized AspyreRx, a prescription-only digital therapeutic treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. AspyreRx was reviewed through the FDA's De Novo pathway and its authorization creates a new class of diabetes digital behavioral therapeutic devices. AspyreRx is expected to launch commercially in Q4 2023.

16:25 EDT E2open jumps 18% to $6.74 after Q1 results and guidance

16:21 EDT E2open names Greg Randolph as Chief Commercial Officer - E2open "announces the appointment of Greg Randolph as chief commercial officer. Randolph will join e2open's executive team on July 31 and report to Michael Farlekas, president and chief executive officer. In this newly created role, Randolph will lead e2open's global commercial organization and be responsible for refining the company's go-to-market strategy and execution, continuing to accelerate growth."

16:15 EDT Ingersoll-Rand names Matt Emmerich CIO - Ingersoll Rand has appointed Matt Emmerich as senior vice president and chief information officer, effective July 17, reporting to Vicente Reynal, chairman, president and chief executive officer. As CIO, Matt will lead the overall strategy and execution of the company's global information technology organization across technology operations, infrastructure, applications and information security. His leadership is critical to accelerating the company's digital transformation and innovation strategies. "Matt has a unique background at the convergence of business and technology," said Reynal. "His established track record in driving transformation while maintaining seamless daily technology operations makes him uniquely qualified to help us solidify IT as a competitive advantage within Ingersoll Rand."

16:13 EDT Galata Acquisition cancels extraordinary general meeting - Galata Acquisition Corp. (GLTA) announced that its extraordinary general meeting of shareholders scheduled on July 12, to vote on, among other things, a proposal to extend the date by which Galata must consummate a business combination has been cancelled. Galata determined that the Extraordinary General Meeting is no longer necessary due to the consummation of the previously announced business combination between Galata and Marti Technologies Inc. on July 10, the company stated. The combined company, Marti Technologies, Inc., formerly known as Galata Acquisition Corp., or "New Marti," a Cayman Islands exempted company, will commence trading of its Class A Ordinary Shares and warrants on the NYSE American Stock Exchange under the ticker symbols "MRT" and "MRTW", respectively, on July 11, the company noted.

16:11 EDT Prothena announces Bristol Myers opt-in for PRX005 worldwide rights - Prothena Corporation (PRTA) announced that Bristol Myers Squibb (BMY) exercised its option under the global neuroscience research and development collaboration to obtain the exclusive worldwide commercial rights for PRX005 and will pay Prothena $55 million. PRX005, which is designed to be a best-in-class anti-tau antibody, specifically targets an area within the microtubule binding region of tau for the potential treatment of Alzheimer's disease. "Earlier this year, as part of our collaboration with Bristol Myers Squibb, we announced topline data from the single ascending dose portion of the Phase 1 clinical trial showing that PRX005 across three dose cohorts was safe and well tolerated with expected pharmacokinetic properties, meeting the primary objectives of the study. We are proud of our pioneering role in targeting this key region within the MTBR of tau and excited that Bristol Myers Squibb have exercised their option for worldwide rights to PRX005," said Gene Kinney, PhD, President and Chief Executive Officer, Prothena. "At Prothena, we will continue advancing our broad portfolio of product candidates for Alzheimer's disease, including PRX012, our next-generation antibody targeting amyloid beta, a well-validated disease pathway, and PRX123 an amyloid beta/tau dual-targeting vaccine with the potential to prevent Alzheimer's disease. We believe that our portfolio is well-positioned to revolutionize the care of patients suffering from this devastating disease."

16:06 EDT NBT Bancorp, Salisbury merger bexpected to close on August 11 - NBT Bancorp announced that it has received regulatory approval to complete the proposed merger of Salisbury with and into NBT and Salisbury Bank and Trust Company with and into NBT Bank, National Association. The Office of the Comptroller of the Currency and the Connecticut State Banking Department both approved the Merger, and NBT received an application waiver from the Federal Reserve Bank of New York. The Merger is expected to close on August 11 subject to the satisfaction of customary closing conditions. A weekend systems conversion will follow with locations of Salisbury Bank opening as NBT Bank offices on August 14.

16:05 EDT Arbutus Biopharma appoints Karen Sims as chief medical officer - Arbutus Biopharma (ABUS) announced the appointment of Karen Sims as chief medical officer and Christopher Naftzger as general counsel and chief compliance officer. Naftzger succeeds Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement litigations. Sims and Naftzger will report directly to William Collier, Arbutus president and CEO, effective immediately. Karen Sims joined Arbutus in April 2017 and has held positions of increasing seniority, including most recently as VP, clinical development, before being promoted to chief medical officer. Naftzger joins Arbutus with more than 25 years of legal experience, including over a decade of experience serving as senior in-house counsel with life science companies. Most recently he served as Interim-CEO, general counsel and corporate secretary of Nabriva Therapeutics (NBRV).

16:02 EDT Latch to reduce U.S. and Taiwan workforce by 59% - The company states: "Following the completion of the Honest Day's Work acquisition earlier this month, Latch, Inc. = announced its commitment to enhancing operational discipline and efficiency within the organization. As part of this strategic initiative, the company expects to reduce its current U.S.- and Taiwan-based workforce approximately 59% by November 1, 2023. HDW's talent philosophy and global team have enabled Latch to quickly execute on cost savings, and the decreased U.S.- and Taiwan-based headcount should allow for additional cost cutting measures to be implemented on SaaS software licenses and other systems."

16:01 EDT Viridian reports 'positive' preliminary data from Phase 1/2 VRDN-001 trial - Viridian Therapeutics announced positive preliminary data from its ongoing Phase 1/2 clinical trial of VRDN-001, an investigational full antagonist antibody to the insulin-like growth factor 1 receptor (IGF-1R), in patients with chronic thyroid eye disease (TED). The Company also announced an amendment to its ongoing THRIVE Phase 3 trial design and provided an update on recent progress of its SC program candidates in TED. "It is quite impressive that patients in the 10 mg/kg and 3 mg/kg dose cohorts experienced reductions in proptosis as well as improvements in their clinical activity scores after receiving just two infusions of VRDN-001," said Kimberly Cockerham, M.D., an Oculoplastic Surgeon specializing in neuro-ophthalmology, orbital oncology and oculofacial restoration at the SENTA Clinic in San Diego, California, and an investigator on the VRDN-001 clinical trial. "Importantly, VRDN-001 was generally well tolerated among all treated patients, who will continue to be evaluated for safety and durability of response. Thus far, these data suggest that VRDN-001 has the potential to become an important new treatment option for managing the signs and symptoms of TED."

15:33 EDT RTX awarded $5M task order under NASA xEVAS contract - Collins Aerospace, an RTX business announced it has been awarded a new task order under NASA's Exploration Extravehicular Activity Services, or xEVAS, contract to modify the company's current spacesuit to support lunar endeavors. The follow-on task order allows Collins to add on to the company's new spacesuit design, developing elements that are compatible for use on the lunar surface as part of NASA's Artemis missions. Collins was awarded a task order valued at $5M, following a proposal process that required the company to identify the methodologies to develop a crossover product.

13:41 EDT EU adopts adequacy decision for EU.U.S. Data Privacy Framework - The European Commission has adopted its adequacy decision for the EU-U.S. Data Privacy Framework. The decision concludes that the United States ensures an adequate level of protection - comparable to that of the European Union - for personal data transferred from the EU to US companies under the new framework. On the basis of the new adequacy decision, personal data can flow safely from the EU to US companies participating in the Framework, without having to put in place additional data protection safeguards. The EU-U.S. Data Privacy Framework introduces new binding safeguards to address all the concerns raised by the European Court of Justice, including limiting access to EU data by US intelligence services to what is necessary and proportionate, and establishing a Data Protection Review Court (DPRC), to which EU individuals will have access. The new framework introduces significant improvements compared to the mechanism that existed under the Privacy Shield. For example, if the DPRC finds that data was collected in violation of the new safeguards, it will be able to order the deletion of the data. The new safeguards in the area of government access to data will complement the obligations that US companies importing data from EU will have to subscribe to. President Ursula von der Leyen said: "The new EU-U.S. Data Privacy Framework will ensure safe data flows for Europeans and bring legal certainty to companies on both sides of the Atlantic. Following the agreement in principle I reached with President Biden last year, the US has implemented unprecedented commitments to establish the new framework. Today we take an important step to provide trust to citizens that their data is safe, to deepen our economic ties between the EU and the US, and at the same time to reaffirm our shared values. It shows that by working together, we can address the most complex issues." Publicly traded companies in the space include Meta Platforms (META), Twitter (TWTR), Pinterest (PINS) and Snap (SNAP). Reference Link

12:34 EDT Surf Air Mobility sees trading on NYSE during week of July 24 - Surf Air Mobility announced that it anticipates its common stock will begin trading on the New York Stock Exchange under the ticker symbol "SRFM" during the week of July 24.

12:00 EDT Aaron's falls -11.8% - Aaron's is down -11.8%, or -$1.80 to $13.48.

12:00 EDT Carvana rises 11.2% - Carvana is up 11.2%, or $3.31 to $32.76.

12:00 EDT SOS Limited rises 16.8% - SOS Limited is up 16.8%, or 76c to $5.28.

10:46 EDT Essential Utilities' Aqua Ohio subsidiary acquires URS system for $25.5M - Essential Utilities announced its Aqua Ohio subsidiary completed the purchase of the Union Rome Sewer system for $25.5M. The system includes a wastewater collection network and treatment plant serving 5,300 connections in Lawrence County, Ohio.

10:00 EDT Dream Finders Homes falls -6.6% - Dream Finders Homes is down -6.6%, or -$1.53 to $21.60.

10:00 EDT FMC Corporation falls -8.6% - FMC Corporation is down -8.6%, or -$8.96 to $95.28.

10:00 EDT Sylvamo rises 7.2% - Sylvamo is up 7.2%, or $2.94 to $43.80.

09:53 EDT Avangrid reaches milestone of 8.6 GW wind, solar capacity - Avangrid reached a capacity of 8.6 GW through its more than 70 wind and solar facilities in operation across the country, which generate the electricity equivalent to powering over 2.8M homes with clean and renewable energy.

09:47 EDT ProShares UltraShort Bloomberg Natural Gas falls -6.4% - ProShares UltraShort Bloomberg Natural Gas is down -6.4%, or -$4.16 to $60.41.

09:47 EDT Ardagh Metal Beverage falls -7.0% - Ardagh Metal Beverage is down -7.0%, or -27c to $3.56.

09:47 EDT Sylvamo rises 5.2% - Sylvamo is up 5.2%, or $2.11 to $42.97.

09:41 EDT Enterprise Products increases quarterly distribution 2% to 50c per unit - Enterprise Products Partners board of directors of its general partner declared a quarterly cash distribution to be paid to Enterprise common unitholders with respect to the second quarter of 2023 of 50c per unit, or $2.00 per unit on an annualized basis. This quarterly distribution will be paid August 14, 2023, to common unitholders of record as of the close of business July 31, 2023. This distribution represents a 5.3% increase over the distribution declared with regard to the second quarter of 2022 and a 2% increase over the distribution declared for the first quarter of 2023.

09:35 EDT ImmunityBio: CIML NK cells plus N-803 may induce tumor regression - ImmunityBio announced findings from a Phase 1 study showing that allogeneic cytokine-induced memory-like natural killer cells used in combination with ImmunityBio's IL-15 superagonist N-803 may induce tumor regression associated with persistent CIML NK cell expansion in advanced head-and-neck cancer patients. The results indicate the potential for a new treatment approach for the disease in advanced cases that currently have extremely poor prognoses. The data from the proof-of-concept study were presented by Glenn J. Hanna, M.D., Medical Oncologist with Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School at the American Association for Cancer Research and the American Head and Neck Society joint conference in Montreal, July 7-8, 2023. This phase 1 single-center trial enrolled 10 patients with R/M HNC regardless of human papillomavirus status who had prior platinum chemotherapy and immunotherapy. Patients in cohort 1 received LD fludarabine and cyclophosphamide on days -6 to -2 prior to haploidentical CIML NK cell infusion on day 0 followed by N-803 starting on day +1 every 21-days for 4-doses. Patients in cohort 2 received the same regimen with a dose of lead-in ipilimumab on day -7. A total of 6 patients were treated in cohort 1 and 4 patients in cohort 2. The primary objective was safety and maximum tolerated dose of CIML NK cells. The secondary objective was objective response rate, progression-free survival, overall survival, and phenotypic expansion and function of adoptively transferred NK cells.

09:33 EDT State Street announces entry into Colombian market - State Street Corporation announced its expansion into Colombia, scaling its servicing capabilities for institutional clients in Latin America. Andres Zambrano Burgl will manage the Colombia office and lead sales in the country. Zambrano is based in Bogota and will report to Maria Ximena Vasquez, State Street's head of Sales for Latin America and The Caribbean ex-Brazil.

09:31 EDT Patriot Battery Metals announces core assay results from Winter Drill Program - Patriot Battery Metals announced core assays for the final set of drill holes completed as part of the 2023 winter drill program at its wholly owned Corvette Property, located in the Eeyou Istchee James Bay region of Quebec. The winter phase of the 2023 drill campaign was focused on the CV5 Pegmatite, located approximately 13.5 km south of the regional and all-weather Trans-Taiga Road and powerline infrastructure. Core assays, for the drill holes reported herein, cover the CV5 Pegmatite's recently defined eastward extension, the high-grade Nova Zone, and the recently defined westward extension. Drill hole CV23-181 and 177 targeted further delineation of the Nova Zone with both returning wide and high-grade intercepts - 108.0 m at 2.44% Li2O, including 37.5 m at 3.58% Li2O or 16.0 m at 4.08% Li2O, and 115.3 m at 1.81% Li2O, including 89.6 m at 2.20% Li2O. The high-grade Nova Zone has been traced over a strike length of at least 1.1 km - from drill holes CV23-132 to 108 and includes multiple drill intersections of 5+ m at greater than5% Li2O, demonstrating the high-grade tenure of this sub-set of the Corvette discovery. As the Company works towards extension of the Corvette discovery, core assay results for the most westwardly drill hole completed to date at the CV5 Pegmatite - CV23-184 - demonstrates high-grades and wide widths persist in this direction, with mineralization remaining open. The Company intends to continue step-out drilling along strike of CV23-184 during the summer-fall drill program. Additionally, drill hole CV23-190, the final hole of the 2023 winter program, also completed over the western areas of CV5, returned strong grades over wide widths - 139.2 m at 1.26% Li2O, including 18.1 m at 2.02% Li2O and 36.2 m at 1.74% Li2O. This drill hole was completed in the opposite direction to the normal drill hole orientation at CV5 and demonstrates the near-surface bulbous nature of the pegmatite in this area, where it is interpreted to exceed 100 m true thickness. Assay results to date over the far eastern portions of CV5 have returned variable grades and widths of lithium mineralized pegmatite. These include 51.2 m at 0.59% Li2O, including 10.1 m at 0.87% Li2O and 9.3 m at 0.91% Li2O, and 27.5 m at 0.40% Li2O, including 3.2 m at 2.22% Li2O. However, results of drill hole CV23-165, as reported herein are very significant and demonstrate the common nature of lithium pegmatites, where high grades may be immediately proximal to low to moderate grades. Further, this drill hole returned six samples greater than 4% Li2O, and three samples greater than 5% Li2O, including an interval of 2.2 m at 5.02% Li2O. These grades are on par with those typically confined to the Nova Zone and outline the considerable potential in this eastward area. Drill hole CV23-165 was completed at the very eastern margins of the CV5 Pegmatite drilled to date and highlight the potential for wide widths at strong grade to continue in this direction, where the pegmatite remains open up-dip, down-dip, and along strike eastwardly/ Through the 2023 winter drill program, the CV5 Pegmatite has been traced continuously by drilling as a principally continuous spodumene-mineralized pegmatite body over a lateral distance of at least 3.7 km and remains open along strike at both ends and to depth along a large portion of its length. This marks a 1.5 km extension of the known mineralized pegmatite along strike since the end of 2022 , and 2.9 km since the end of 2021. For added perspective, this growth in strike length since the initial drill program in 2021 is presented in Figure 4. As previously announced, the Company is advancing towards an initial mineral resource estimate for the CV5 Pegmatite. All core sample assays have now been received from the lab with the drilling dataset undergoing final validation and geological model on the final revision. The next steps in the process include geostatistics on the validated database followed by creation of the block model and interpolation of the lithium and tantalum grades, resource classification, determination of an appropriate cut-off grade and pit parameters, and finally constraining the block model with a pit to determine the official mineral resource estimate numbers. At this time, the Company anticipates an announcement on the mineral resource estimate in a few weeks time.

09:24 EDT Nano Dimension increases special tender offer for Stratasys to $24.00 per share - Nano Dimension (NNDM) announced the following actions that highlight a clear path to maximizing value for Stratasys (SSYS) shareholders: "Nano Dimension has increased the offer price of its special tender offer from $20.05 to $24.00 per share in cash, less any required withholding taxes and without interest, to purchase between 31.9% and 36.9% of the outstanding ordinary shares of Stratasys. The increased price represents a premium to all relevant Stratasys historical trading levels, including an 85% premium to the unaffected 60-day VWAP as of March 3rd, 2023. Nano's special tender offer is the most compelling offer for Stratasys shareholders and remains the only alternative available that provides certain, near-term cash value at a significant premium and provides the quickest path for Stratasys shareholders to realize value. The Expiration Date of the offer period remains unchanged at 5:00 p.m., New York Time, on July 24th, 2023. The successful completion of the special tender offer would increase Nano Dimension's beneficial ownership of Stratasys to between 46% and 51% of the outstanding ordinary shares, inclusive of the approximately 14.1% of Stratasys' outstanding ordinary shares that Nano Dimension currently owns. Tendering shares to NANO will deliver 220% more cash to Stratasys shareholders in the near-term than any currently available alternative, including the cash from a proposed 3D Systems, (DDD) deal, and preserves the ability to generate future value creation through strategic M&A opportunities. As the largest shareholder of Stratasys, Nano Dimension intends to support a review of strategic alternatives to further enhance shareholder value, including through industry consolidation, possibly through a negotiated combination with 3D Systems, following the successful completion of the special tender offer. Nano Dimension OPPOSES Stratasys' proposed combination with Desktop Metal (DM), which, as structured, is highly dilutive and greatly overvalues Desktop Metal's cash-burning business. Nano Dimension has nominated 7 highly qualified directors with extensive track records of value creation for election to the Stratasys Board of Directors at Stratasys' Annual General Meeting to be held on August 8th, 2023. They are nominated with the intention of replacing the majority of the Stratasys Board, which Nano believes has neglected its fiduciary duties to the detriment of Stratasys shareholders' interests. All of Nano's nominees have previously served as CEOs or in "C-suite" positions, through which they have created demonstrable increases in long-term shareholder value. Almost all of Nano's candidates have multiple decades of global business experience in technology, finance, M&A and operations in manufacturing and related sectors. The nominees include: Ze'ev Holtzman, who brings deep expertise in private equity, venture capital and investment banking. Mr. Holtzman founded a pioneering investment banking firm, a leading VC firm focused on early-stage innovation technology, as well as the premier database on high-tech, venture capital, startup, and private equity ecosystems. Zivi Nedivi, who has decades of international business leadership experience. He formerly served as CEO of several technology companies, including Cyalume Technologies Inc. and Kellstrom Industries, Inc., and formerly served as COO of Lumenis Ltd. Hanan Gino, who has prodigious experience as a CEO at international technology corporations, including Verint Security Systems and Kitov Systems as well as senior executive and head of all commercial divisions for over two decades at Orbotech Ltd. Tomer Pinchas, ex-manager at PricewaterhouseCoopers New York, who brings more than 18 years of global experience in finance, M&A and operations management and previously served as CFO of multiple technology companies, including Kryon Systems LTD, myThings Inc, and DVTEL. Nick Geddes, who co-founded the renowned industrial inkjet company Global Inkjet Systems, with leading R&D capabilities, inkjet products and services, and has been CEO and CTO for over 15 years with deep knowledge and experience leading and bringing together multi-disciplinary teams to partner with customers. Yael Sandler, who brings extensive experience in leading finance and operations roles for public and private companies, having formerly held various positions at KPMG while also being a Certified Public Accountant in Israel. Yoav Stern, who is a seasoned executive with a proven track record of leadership over three decades, having served as CEO and Chairman as well as an active hands-on investor in high-tech companies, specializing in machine vision, fiber optics, defense-tech, communication solutions, aerospace, and homeland security."

09:19 EDT inDrive selects Nuvei as payments partner in Latin America - Nuvei Corporation has been selected by inDrive as its payments provider for payouts to its drivers in Latin America. Nuvei is enabling inDrive to offer a comprehensive range of payout options, including payments to cards and all relevant alternative payment methods in the Latin America region through a single integration.

09:16 EDT Tejon Ranch reappoints Michael Houston SVP, general counsel, corporate secretary - Tejon Ranch announced the reappointment of Michael Houston as Senior Vice President, General Counsel and Corporate Secretary. Houston previously held those positions at the Company for almost five years beginning in 2016. He left Tejon Ranch in 2021 to join the Southern California Association of Governments, where he served as Chief Counsel and Director of Legal Services. He will rejoin the Company on August 21, 2023.

09:10 EDT Acasti Pharma: WuXi Clinical to conduct STRIVE-ON Phase 3 trial for GTX-104 - Acasti Pharma announced WuXi Clinical Development, a wholly owned subsidiary of WuXi AppTec, will conduct Acasti's STRIVE-ON Phase 3 safety trial for GTX-104. GTX-104 is Acasti's novel, injectable nimodipine formulation for intravenous infusion that addresses high, unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. STRIVE-ON will evaluate GTX-104's comparable safety and tolerability profile relative to oral nimodipine in patients hospitalized with aSAH.

09:08 EDT Brilliant Earth announces opening of four new ground floor showrooms - Brilliant Earth Group announced the opening of four new ground floor showrooms. The Company continues to expand its retail footprint to bring customers more access to its physical retail shopping experience. These showrooms, located in Fairfax, VA, Miami, FL, Chicago, IL, and Walnut Creek, CA, bring Brilliant Earth's total showroom count to 34 locations across the country.

09:07 EDT Kartoon Studios announces broad debut of 'Shaq's Garage' - Kartoon Studios announced the broad debut of "Shaq's Garage," starring and executive produced by the Shaquille O'Neal, across Kartoon Channel! platforms, following its exclusive premiere on Pluto TV throughout June. Shaq's Garage premiered the first 13 episodes of season one exclusively on Pluto TV, delivering more VOD viewers than all of Kartoon Channel!'s other titles combined, while increasing Kartoon Channel!'s weekly audience by over 50%. Additionally, the series captured the top 3 most viewed episode slots on Kartoon Channel! over the last 90 days. Beginning today, Shaq's Garage" is now available to Kartoon Channel! audiences across ALL major platforms, including Amazon Prime Video, Roku and The Roku Channel, Apple, Google, Android, Amazon Fire , LG, Samsung, Kartoonchannel.com, and more.

09:06 EDT PDF Solutions announces acquisition of Lantern Machinery Analytics - PDF Solutions announced the acquisition of Lantern Machinery Analytics, a privately-held provider of automated image analysis and feature extraction AI/ML software for critical inspection and metrology steps at battery cell development and manufacturing processes for the electric vehicle industry. "We are pleased to welcome Lantern Machinery Analytics to the PDF Solutions team," said Dr. John Kibarian, President, CEO, and co-founder of PDF Solutions. "AI-powered vision inspection is the future of process control for electric vehicle battery cell manufacturing. The addition of Lantern Machinery Analytics to the PDF Solutions' technology portfolio highlights our continued commitment to deliver the highest level of tool and manufacturing intelligence to enable a growing base of customers, now more squarely within battery, to realize the benefits of Industry 4.0."

09:05 EDT eBay announces new trading card submission service for the eBay vault - eBay announces a new trading card submission service for the eBay vault. Collectors, investors and professional sellers can now submit eligible graded cards valued at $250+ directly to eBay's state-of-the-art facility and digital marketplace. The new service expands eligibility for the eBay vault beyond cards directly purchased on the marketplace, and also covers graded autograph, relic, and patch cards. With eBay's new submission service, collectors can easily send an individual card - or their entire collection - to the eBay vault, for specialized long-term storage, expert third-party authentication, and streamlined transactions.

09:05 EDT GeoVax Labs presents Gedeptin clinical data at the AACR-AHNS - GeoVax Labs announced the presentation of Phase 1/2 clinical trial data for GeoVax's gene therapy candidate, Gedeptin at the American Association for Cancer Research, AACR, and the American Head and Neck Society, AHNS, joint Head and Neck Cancer Conference in Montreal, QC, Canada. The presentation, titled "Phase 1/ 2 study of Ad/PNP with fludarabine for the treatment of head neck squamous cell carcinoma", describes the evaluation of Gedeptin as an experimental therapy for refractory solid tumors. The ongoing Phase 1/2 trial is evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma, with tumor(s) accessible for injection and no curable treatment options. The poster presentation, highlighted the following data: 8 patients have been enrolled in the study to date. No dose limiting toxicities or serious adverse events are definitively attributable to treatment. Additionally, no adverse events above grade 3 severity have been reported. Up to 5 cycles of Gedeptin treatment have been administered without limiting sequelae. Intratumoral expression of the PNP transgene by RT-PCR has been established in treated tumors studied to date. Impairment of tumor growth in targeted lesions was seen in 5 of 7 patients; tumor response assessment in one patient remains under study.

09:03 EDT Fresenius Medical names Martin Fischer as CFO, succeeding Helen Giza - Fresenius Medical has appointed Martin Fischer as CFO as of October 1, 2023. He will succeed Helen Giza who was appointed as CEO and Chair of the Management Board in December 2022 and continues to serve as acting CFO, until her successor will join. Martin Fischer will be based in Bad Homburg, Germany and will assume responsibility for the Global Finance Organization of Fresenius Medical Care. Upon effectiveness of the company's proposed change of form from KGaA to German stock corporation, Martin Fischer will become a member of the Management Board of Fresenius Medical Care AG. Martin Fischer has been Head of Finance for Siemens Healthineers Diagnostics Division based in Tarrytown, NY, U.S. since 2019.

09:01 EDT Eloxx Pharmaceuticals announces publication on its TURBO-ZM platform - Eloxx Pharmaceuticals announced that Cancer Research Communications has published "A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer". "We are incredibly pleased with this publication, as it highlights the power of our TURBO-ZM platform to target the human ribosome to develop new potential therapeutics. Importantly, for the first time, we also demonstrate that MYC overexpressing cancers can be targeted by exploiting ribosome heterogeneity, as ZKN-157, a novel RMA, demonstrated activity against subtypes of colorectal cancer," said Vijay Modur MD, PhD, Head of R&D of Eloxx. "As MYC is dysregulated in approximately 70% of human cancers, this research provides opportunities to selectively target MYC-driven cancers with a novel mechanism and has potential for synergy with existing cancer therapies."

08:52 EDT Hillstream BioPharma appoints Sireesh Appajosyula as COO - The Company announced the appointment of Sireesh Appajosyula, Pharm.D.as as COO. Previously, he spent eight years at Salix Pharmaceuticals, Inc. in various roles including medical & clinical affairs, product commercialization and business development culminating in Salix's acquisition for $16 billion by Bausch Health.

08:51 EDT Hillstream BioPharma announces strategic reprioritization of pipeline - Hillstream BioPharma announced a strategic reprioritization of its pipeline and provided a corporate update. The strategic assessment took into account, the pipeline's near-term value creation opportunity and other factors. Hillstream will focus its pipeline on advancing novel oncology assets with the greatest potential and strong competitive profiles to address unmet needs across multiple solid tumors, such as bispecific antibodies and ADCs targeting novel conformational epitopes on high value validated targets, HER2 and HER3, with a more potent Bystander Effect. Bispecific antibodies refer to a diverse group of molecules that recognize distinct epitopes on two different antigens, such as HER2 and HER3. These validated targets have been extensively studied and belong to the ERBB receptor tyrosine kinase family and are exploited by cancer cells to promote tumorigenesis and metastasis. HER2, an extensively studied and validated target, has multiple approved therapeutics for solid tumors. Meanwhile, emerging evidence suggests that HER3 plays a central role through interacting with neighboring receptors. While HER3 has little to no tyrosine kinase activity on its own, its activation to promote tumors depends on heterodimerization or locking into place with HER2 and EGFR, which is believed to unlock its cancer-causing potential. Hillstream's lead asset, HSB-3215 is designed as a bispecific humanized immunoglobulin containing two arms targeting the extracellular domains of HER2 and HER3. HSB-3215 binds to both overlapping and different epitopes on HER2 when compared to trastuzumab, the first approved antibody against HER2, while adhering to novel epitopes on HER3, thus creating novel conformational epitopes. The Company intends to develop this novel BsAb and file an IND application with the US FDA late next year. By exploiting the "Bystander Effect", a key aspect of ADCs which has been recently highlighted by the improved clinical efficacy of Daiichi Sankyo/AstraZeneca's ENHERTU, the Company plans to optimize its BsAb pipeline with BiSpecific ADCs, i.e. BiSpecific antibodies conjugated with novel toxin payloads which are optimized to generate a more powerful Bystander Effect. ADCs are comprised of a targeting antibody chemically conjugated via a proprietary linker to a powerful, cancer-killing compound/toxin. With a BsAb backbone utilizing HSB-3215, the Company intends to develop novel ADCs, targeting HER2/HER3 and better direct a payload to cancer cells overexpressing these receptors, while healthy cells don't take up the unwanted compound. Hillstream also intends to further enhance its previously announced collaborations with Applied Biomedical Science Institute and Minotaur to develop novel bovine-derived biologics in multiple formats against highly validated targets, including PD-1, HER2 and TROP-2, referred to as PicoKnobs. An update regarding these collaborations will be announced during an R&D Day in the third quarter.

08:46 EDT Vuzix receives OEM purchase order for engineering services from U.S. company - Vuzix is pleased to announce the receipt of an OEM purchase order for engineering services and waveguide and display engine products from a U.S.-based company that is a leading provider of sophisticated digital imaging products for aerospace and defense, and instrumentation solutions across multiple commercial and industrial systems. This order, which represents the first Vuzix has received thus far from this company, is for waveguides and optical engines that are intended to be designed into a customized head mounted display solution for multi-discipline applications.

08:42 EDT SharpLink Gaming announces changes to Footballguys collaboration - SharpLink Gaming announced changes to its collaboration with Footballguys, providing for a much broader offering of fun, engaging, high stakes fantasy football championships for the companies' combined audiences of sports fantasy fans. On June 7, 2023, SharpLink announced the formation of a strategic partnership with Footballguys and their plans to produce and market a new 17-week Footballguys Championship contest with an entry fee of $350 featuring 12 teams per league with a 20 round online draft. The companies have elected to forgo that contest in favor of offering two different high stakes contests. Anyone who previously signed up for a future Footballguys Championship team and who has already drafted in a league will be offered the choice to request a full and immediate refund, or transfer their entry fees into either or both of the following sports fantasy games: The newly branded Footballguys Best Ball Championship, formerly known as the NFFC Best Ball Championship, has been owned and hosted by SharpLink's SportsHub fantasy sports division for the past two decades. Rhe entry fee is $150 per player and the contest will feature a $30,000 grand prize and over $350,000 in other cash prizes paid out to the top three leagues and top 20 players finishing overall AND/OR SharpLink's Rotowire Online Championship has been a fantasy football fan favorite contest for the past 14 consecutive years. The entry fee is $350 and the grand prize will be $250,000 with the next top 45 players taking home between $300 and $50,000, depending on where they finish on the leaderboard.

08:40 EDT Innovative Solutions buys several Honeywell Product lines, sees 2024 accretion - Innovative Solutions & Support (ISSC) announced that it has entered into an exclusive license and acquired key assets for certain Inertial, Communication and Navigation product lines from Honeywell International (HON). Shahram Askarpour, Chief Executive Officer, said, "We are pleased to announce the exclusive licensing of these product lines from Honeywell Aerospace. This is a unique opportunity that enhances our current offerings in the Air Transport, Military and Business Aviation markets...Under the asset purchase and license agreement, IS&S will license the exclusive Intellectual Property rights to manufacture, upgrade and repair certain Honeywell Inertial, Communication and Navigation products. The purchased assets include existing inventory as well as test, tooling and other equipment required to manufacture, repair, and upgrade the products. Mike Linacre, Chief Financial Officer, added, "These product lines have attractive margin profile characteristics that are an essential element of our strategy. Consequently, once they've been integrated into our operations, we expect the transaction to materially contribute to our revenues and EBITDA. We also expect the resulting EPS to be accretive in fiscal 2024, with the potential for additional net income increases in future years from various synergies. Coincident with this acquisition, IS&S has secured bank facilities to maintain ample liquidity for ongoing operations and potential future acquisitions. These facilities and cash on hand were used to fund the total purchase price for the transaction."

08:37 EDT BYND Cannasoft announces completion of laboratory testing phase for EZ-G - BYND Cannasoft Enterprises announced the successful completion of the laboratory testing phase aimed at optimizing the various sensors in its innovative EZ-G device. The EZ-G device, a therapeutic solution utilizing AI and machine learning, has shown promise in releasing low concentrations of CBD oils, including hemp seed oil and other natural oils, to potentially address specific women's health issues. Throughout the laboratory testing phase, the Company conducted comprehensive experiments as part of the prototype development of the EZ-G device. The focus was on assessing the functionality and performance of the assembled sensors within the device, capable of detecting indicators such as temperature, heart rate, contractions, and fluids. "We are thrilled with the successful completion of the laboratory testing phase for the EZ-G device," said Yftah Ben Yaackov, CEO and Director of BYND Cannasoft. "This accomplishment validates our dedication to harnessing advanced technology to improve women's health. We are excited to move forward with human trials, as we believe the EZ-G device has the potential to revolutionize therapeutic approaches for women's health issues."

08:36 EDT Omniq enters definitive agreement to acquire Tadiran Telecom - OMNIQ announced that it has signed a definitive agreement to acquire Tadiran Telecom, an international provider of Advanced Unified Communications and Collaboration, UC&C, Solutions enhancing its software. Shai Lustgarten, the CEO of omniQ, commented: "With the addition of Tadiran, we will possess a comprehensive proprietary communication solution that enables us to better serve our customers. Our platform technology utilizes 3 steps, we Sense, Identify and Act. With the addition of Tadiran, we can now add audio, cellular and WIFI signals to our current sensors which today include camera's, scanners, RFID and Bluetooth technologies allowing us to analyze the digital data in greater detail and at faster speeds. This significantly enhances our ability to manage events and mitigate risks at all levels. The new smart automation is a unique solution into our supply chain, traffic management, retail and hospitality customers, allowing us to provide superior service with more accurate and faster sensing, identification and action. As omniQ continues to drive automation for our customers, this acquisition not only allows us to meet the existing organizational communication needs of our current customers but also enables us to create automation through real-time AI communication sensing. This is important as it provides us the capability to identify and respond faster and with greater accuracy. By leveraging the sensing and digitization of communication data and identifying trends at the communication AI level, we can take prompt and precise actions. This capability is crucial in our commitment to delivering predictive and proactive actions."

08:35 EDT Mobiquity Technologies announces results of political campaigns with ElecTech - Mobiquity Technologies announced the results of its political campaigns utilizing ElecTech. Each candidate supported by Mobiquity's proprietary AI platform won their respective races and are poised to move on. Mobiquity recently deployed ElecTech's proprietary AI election technology in the following elections which concluded with victorious candidates: A state Supreme Court election in Pennsylvania, where the campaign effectively leveraged Connected TV for voter targeting. A City Council election for Kansas City's Northland, utilizing advanced electoral analytics. A state Senate General Election in Virginia, where comprehensive electoral data models were used for campaign planning and execution. Dean Julia, CEO of Mobiquity Technologies, said, "Our goal is to demonstrate the impact of advanced AI technology and sophisticated predictive algorithms in the electoral domain. We are working with exceptional candidates who have exceptional qualifications, so while we cannot claim sole credit, ElecTech remains unbeaten in this small, yet significant sample set thus far."

08:33 EDT SP Plus awarded five-year contract extension at McCormick Place - SP+ Corporation announced a five-year contract extension with its long-term parking client McCormick Place, in Chicago, Illinois. "We greatly value the relationship we have with MPEA, and the role SP+ has in providing our hospitality and event management services to the McCormick Place campus as it has evolved over the years," said James F. Buczek, Chief Operations Officer, Commercial Division, SP+ Corporation. "We are excited about the opportunity to contribute to additional service and technology enhancements in the coming years."

08:32 EDT Commercial Metals CEO Barbara Smith to retire, Peter Matt to succeed - The Board of Directors of Commercial Metals Company (CMC) announced that Barbara Smith, the company's CEO and Chairman, has chosen to retire as CEO and has been appointed Executive Chairman of the Board, effective September 1, 2023. The board unanimously voted to appoint Peter Matt, the company's President, to the role of CEO and President of the company effective September 1, 2023. Matt will also continue as a member of the company's Board of Directors, which he joined in June 2020. Prior to serving as the company's President, Matt served from January 2017 to April 2023 as Executive Vice President and CFO of Constellium (CSTM), a global aluminum fabrication company

08:31 EDT Infinity Pharmaceuticals provides additional information on MARIO-8 study design - Infinity Pharmaceuticals (INFI) announced further design features of its Phase 2 MARIO-8 study in SCCHN. The adaptive design of the MARIO-8 study is intended to optimize the dose of the oral drug candidate, eganelisib, in combination with the standard dose of pembrolizumab, in 40-70 patients in Part A of the study. The dose optimization phase of the study will evaluate two dose regimens of eganelisib; a 30mg regimen, dosed daily for two out of every three weeks, and a 20mg regimen, with continuous daily dosing. The company has received FDA feedback and, pending final FDA review and subject to the successful close of the company's proposed merger with MEI Pharma (MEIP), preliminary safety and efficacy data to inform the dose selection are expected in the second half of 2024. The selected eganelisib dose, in combination with pembrolizumab, will be further evaluated in Part B of the study in approximately 100 additional patients, with the primary endpoint of overall survival and secondary endpoints of progression free survival and safety.

08:29 EDT Inter Parfums enters worldwide fragrance license deal for Roberto Cavalli brand - Inter Parfums announced that it has entered into an exclusive worldwide fragrance license for the Roberto Cavalli brand, effective July 6. Based in Florence, Interparfums Italia, the Company's wholly owned subsidiary, will manage the Cavalli fragrance business, in keeping with the Company's strategy to develop an Italian brand hub. Established in 1970, Roberto Cavalli is a globally recognized Italian luxury lifestyle brand incorporating apparel for women, men and children, fashion accessories, home collections, and fragrances. Roberto Cavalli fragrances debuted in 2002 introducing the first of a series of successful initiatives under the Roberto Cavalli and Just Cavalli brands.

08:21 EDT Eskay Mining sells five mining claims to Skeena Resources for $4M - Eskay Mining (ESKYF) has sold 5 mining claims in the Golden Triangle area of BC to Skeena Resources (SKE) in consideration for aggregate cash payments of $4M. The initial consideration of $2M was paid to Eskay on closing, a further $1M is payable on October 31, 2023 and the final $1M payment is payable on December 31, 2023. Eskay retains a 2% net smelter returns royalty in the Claims. Skeena can purchase 50% of the Royalty at any time for $2M. In addition, Eskay will not be required to pay any road use fees to Skeena for its use of the Eskay Creek Road for the five year period ending December 31, 2027, provided that its road use those years is consistent with its road use in 2022. Four of the Claims are north and west of the Skeena Eskay Creek Project and one of the Claims is adjacent to the west side of the Skeena Eskay Creek Project.cThe Company also anniybces the Eskay exploration team has been mobilized to the camp and is preparing for the 2023 exploration and drilling season at the Company's Consolidated Eskay Project, Golden Triangle, BC.

08:17 EDT Panbela: DSMB recommends Phase III ASPIRE trial continue without modification - Panbela Therapeutics announces that the independent Data Safety Monitoring Board of the Phase III ASPIRE clinical trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has completed its pre-specified review of safety data for treated patients in the trial. The DSMB has recommended that the study continue without modification. The ASPIRE Trial is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma

08:16 EDT Xometry expands AI-powered Xometry Instant Quoting Engine - Xometry announced the continued expansion of its AI-powered Xometry Instant Quoting Engine to include instant-quoting of inserts, multi-part assemblies, and expanded sheet-cutting processes. The enhanced features allow buyers to instantly get pricing and lead times on CNC, sheet metal and sheet-cut parts with standard inserts while also analyzing multi-party assemblies, further accelerating Xometry's assembly production work. The expanded feature set:Allows buyers to auto-quote CNC, sheet metal and sheet-cut parts with standard inserts; Enables buyers to isolate and specify individual parts on multi-part files or assemblies; And delivers expanded sheet-cutting options to include a wider array of metal, composite and rubber materials. Xometry's sheet-cutting service can cut a variety of materials using the latest laser and waterjet-cutting technologies.

08:14 EDT BioVie to present data on NE3107 in DNA methylation of specific genes - BioVie announced that a poster detailing the genetic basis for how its drug candidate NE3107 regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements will be presented this weekend at the Alzheimer's Associate's International Conference to be held in Amsterdam July 16-20, 2023. In a poster presentation titled Treatment-Induced Epigenetic Modifications in MCI and Probable Alzheimer's, presenters will show how patients with clinical dementia treated with NE3107 for 3 months saw significant reductions in the level of DNA methylation, and that such reductions were significantly correlated with observed improvements in various cognitive measures and biomarkers. Inflammation has been shown to be associated with the hypermethylation of our DNA, which in turn has been shown to impact a wide range of diseases, including various forms of cancers, age-related cognitive impairment and dementia, Parkinson's disease, cardiovascular disease, COPD and respiratory disease, chronic kidney disease, inflammatory bowel disease, sepsis, and many others. The new data to be presented details how NE3107 may potentially change or affect the degree of methylation of specific genes that are correlated with various markers of disease.

08:12 EDT Houlihan Lokey acquire 7 Mile Advisors or 7MA , no terms - Houlihan Lokey has agreed to acquire 7 Mile Advisors 7MA an independent advisory firm that provides a range of investment banking services to clients across the IT services sector. The transaction, signed July 7, further enhances Houlihan Lokey's deep industry expertise in IT services and expands the firm's geographic footprint. The deal is expected to be completed this quarter following regulatory approval.

08:11 EDT Quest Resource appoints Perry Moss as SVP, sales - Quest Resource Holding Corporation (QRHC) appointed Perry Moss as Senior Vice President of Sales. At Quest, Moss will be responsible for driving and maximizing revenue growth and overseeing sales strategies. Most recently, Moss was Co-Founder and Chief Advisor to Rubicon Technologies (RBT).

08:10 EDT Curaleaf announces strategic national rebrand of Select cannabis lifestyle brand - Curaleaf Holdings unveiled the strategic national rebrand of its Select cannabis lifestyle brand across 15 U.S. states. Additionally, the company announced the launch of Select's all-in-one, two-gram proprietary vape technology, Select Briq, as well as the expansion of its Select X Bites edibles portfolio with the launch of Live Rosin X Bites and High Dose X Bites.

08:09 EDT KAMO Power deploys Infinera's XTM Series to upgrade rural broadband network - Infinera announced that KAMO Electric Cooperative is deploying Infinera's XTM Series on its 2,700-route-mile rural network to serve its 17 member cooperatives across northeast Oklahoma and southwest Missouri. The deployment upgrades KAMO Power's network, providing the cooperative with an open optical network that delivers high-capacity, reliable, and secure transport services.

08:08 EDT Mullen Automotive announces start of 2023 'Strikingly Different' EV Tour - Mullen Automotive announces the beginning of the 2023 "Strikingly Different" EV Tour, which will commence on Aug. 20 in Austin, Texas. With the tremendous success of the Mullen FIVE tour in 2022, additional EVs have been added to the 2023 segment, including: Mullen FIVE EV Crossover; Mullen FIVE RS High-Performance Sport EV Crossover; Mullen GT High-Performance Electric Sports Car; Mullen ONE Class 1 Commercial EV Cargo Van; Mullen THREE Class 3 Commercial Low Cab Forward; Bollinger B2 Electric Pickup Truck. The tour will commence late summer on Aug. 20, 2023, and continue through November 2023, and will cover the East Coast, Midwest and Northwest before finishing up in California. Initial announced locations include: Austin, TX - Aug. 20 & 21 at Circuit of Americas; New Orleans, LA - Aug. 29 & 30 at NOLA Motorsports Park; Washington, D.C and Philadelphia, PA - Sept. 18 & 19 at Dover Motor Speedway; Las Vegas, NV - Oct. 31 & Nov. 1 at Las Vegas Motor Speedway; Additional tour stops on East Coast, Midwest, Northwest and West Coast to be announced soon.

08:07 EDT Connect Biopharma announces presentation of four posters - Connect Biopharma announced it presented four posters at the 25th World Congress of Dermatology being held in Singapore from July 3-8, 2023. Poster presentation Summaries: Poster presentation 3240#: "Rademikibart, a next-generation IL-4Ralpha antibody, achieved all primary and secondary endpoints in a randomized pivotal trial for moderate-to-severe atopic dermatitis in China." This poster presentation reported the Week 16 primary and key secondary efficacy outcomes and key safety data demonstrating that rademikibart achieved all endpoints in the primary analysis population of adults with moderate-to-severe AD. Poster presentation #3242: "Eczema Area and Severity Index scores improved, and encouraging safety and tolerability were observed, across 16 weeks of treatment with rademikibart for moderate-to-severe atopic dermatitis: A pivotal trial in China." This poster included new efficacy data showing highly significant improvement with rademikibart in total EASI score change and in EASI score per AD sign in the primary analysis population, as well as new safety data indicating that rademikibart was well tolerated. Poster presentation #3247: "Improvements in investigator-rated outcomes across 16 weeks of treatment with rademikibart for moderate-to-severe atopic dermatitis: Results from a pivotal trial in China." This poster presentation showed the time course of the statistically significant improvements in investigator-assessed outcomes with rademikibart across the initial 16-week treatment period in the adult population. Treatment with rademikibart led to rapid improvements in IGA 0/1, EASI, BSA and SCORAD, all without plateauing by Week 16. Poster presentation #3243: "Improvements in patient-reported outcomes across 16 weeks of treatment with rademikibart for moderate-to-severe atopic dermatitis: Results from a pivotal trial in China." The poster discussed the statistically significant improvements observed in PROs, as assessed by PP-NRS, DLQI and POEM questionnaires, with rademikibart treatment over the initial 16-week treatment period in adult population.

08:05 EDT Calumet Specialty Products provides Q2 update on Specialties business - The Northwest Louisiana area endured extreme weather consisting of tornadoes and hurricane-force straight-line wind events during the quarter, the most recent of which left over 250,000 people without power. These weather events resulted in the repeated loss of external electrical supply to all four facilities that make up our Northwest Louisiana specialties complex. Disruptions during the quarter resulted in reduced production volume of approximately 500,000 barrels. "Despite the loss of power and property damage across the region, including to a number of our employees' homes, the team rallied to restart and normalize operations, complete the turnaround at our Cotton Valley Solvents facility, and advance maintenance at our Princeton and Shreveport facilities," said Borgmann. Our investment program to further harden and integrate our unique specialties complex continues. While we are approximately halfway through the three-year program, the foundational work completed thus far was instrumental in returning to normal operations. "Meeting robust specialty product demand during these disruptions was a significant challenge, and I am proud of how our entire team responded" said Scott Obermeier, EVP Specialties. "With the plants running, we are now rebuilding inventories and focused on capturing the solid market demand in front of us. Performance Brands operations in Northwest Louisiana also experienced several power outages, which were more than offset by proactive inventory management and strong demand. During these extreme events we were able to prioritize needed deliveries of fuel to emergency responders and donate supplies of TruFuel to assist with clean-up efforts." Strategically, the company continues to progress. "With strong market conditions and assets in full operation, we expect to generate significant cash flow from both Specialties and Montana Renewables in the second half of the year," said Borgmann. "Further, our Montana Renewables monetization strategy remains on track. With proven operations and a tangible growth strategy, the appeal of Montana Renewables to potential investors, including the public market, continues to grow. This combination of expected strong cash flows and a path to potential monetization leaves Calumet well positioned to achieve its strategic objectives of permanently de-levering the business and unlocking value for our unit holders."

08:04 EDT Paratek Pharmaceuticals announces modification of BARDA contract - Paratek Pharmaceuticals announced a modification to its Project BioShield contract with the Biomedical Advanced Research and Development Authority, BARDA, part of the Administration for Strategic Preparedness and Response, ASPR, within the U.S. Department of Health and Human Services. The modification provides new development milestones associated with the achievement of specific anthrax development milestones for the next BARDA procurement of NUZYRA. BARDA and Paratek have agreed the next procurement of NUZYRA anthrax treatment courses will be split into two equal procurements based on the achievement of specific development milestones toward both treatment and post-exposure prophylaxis indications of pulmonary anthrax. The first of these procurements will be triggered by the delivery of positive top-line data from a dose-ranging efficacy study for PEP of inhalation anthrax in non-human primates. The company expects this data to be available in the first quarter of 2024. The second of these procurements will be triggered by BARDA's receipt of positive top-line data from a combination of two studies, a dose-ranging efficacy study in NHPs and a pivotal efficacy study in rabbits for the treatment of inhalation anthrax, which the company anticipates could be available as early as the fourth quarter of 2024. The trigger for the final procurement of NUZYRA continues to be Paratek's receipt of sNDA approval from the FDA for the treatment of inhalation anthrax. The company will provide further specificity on these timelines as the anthrax development program progresses.

08:03 EDT CBAK Energy Technology unit enters strategic agreement with Echom - CBAK Energy Technology announced that its subsidiary, Nanjing CBAK New Energy Technology Co., has entered into a strategic agreement with Guangzhou Echom Science & Technology Co., Ltd., a well-known industrial design group in China. According to the terms of the collaboration, Echom will purchase approximately RMB 180M worth of CBAK Energy's cylindrical lithium-ion batteries over the next three years, primarily the 32140 and 26700 series. As part of the arrangement, Echom is obligated to prioritize CBAK Energy's batteries in its self-developed new energy storage products and ensure that over 50% of its relevant products utilize CBAK Energy's batteries. In exchange, Nanjing CBAK will guarantee a consistent and uninterrupted supply of the specified battery products for the duration of the agreement.

08:02 EDT Tritium applauds proposed Texas NEVI funding requirement for connectors - Tritium DCFC supports the Texas Department of Transportation's proposal to require both the Combined Charging Standard and North American Charging Standard connectors for each National Electric Vehicle Infrastructure Formula Program-funded charger in the state, and supports the Texas Transportation Commission's authorization of this proposal. To assist the State of Texas and other states considering this requirement, Tritium is committed to providing NACS connectors on its chargers by late 2023 or early 2024. On the heels of the Texas Department of Transportation's proposal, the Kentucky Transportation Cabinet issued an addendum to the state's NEVI request for proposal to require NACS connectors.

08:02 EDT Canoo expands partnership with U.S. Department of Defense - Canoo Technologies announced that the U.S. Department of Defense's Defense Innovation Unit significantly expanded the scope of its previously announced partnership. The company says it has leveraged it advanced commercial battery and integration expertise to deliver to the Department of Defense partners a technologically advanced battery pack that can be scaled for use on operational military platforms and will set the stage for standardization of energy dense lithium batteries for the U.S. Navy. This follows DIU's testing and analysis of Canoo's proprietary technology since February 2023.

07:58 EDT Helen of Troy jumps 10% to $124.50 after Q1 results beat estimates - The company also reaffirmed FY24 guidance.

07:47 EDT Hyzon Motors completes testing of first nine single-stack 200kW Fuel Cell System - Hyzon Motors announced the successful completion and factory acceptance testing of the first nine single-stack 200kW Fuel Cell System B-samples at its production and innovation center in Bolingbrook, IL. By achieving this milestone, Hyzon remains on track to declare Start of Production and commercialization of its innovative FCS in 2024. The successful completion of testing of Hyzon's nine 200kW FCS B-samples in the first half of 2023 demonstrates consistent progress toward commercial production. This achievement follows the commissioning of Hyzon's proprietary, automated roll-to-roll Membrane Electrode Assembly production line including in-line inspection and the installation of its single cell and fully automated fuel cell stack manufacturing lines. Progression of the 200kW FCS B-samples validates the design, equipment, and operating procedures, which are all critical to the final tooling and production of C-samples and the eventual commercialization of the FCS. Additionally, we believe it shows growth in the company's prototype assembly rate, with six of the B-samples produced and tested in Q2 2023, an increase from three in Q1 2023. Hyzon is positioning to increase its FCS manufacturing rate with the installation of additional full and semi-automation equipment in the assembly and inspection processes, which is already underway. It expecst the continued standardization of design around the 200kW FCS powertrain components will expedite production and the company expects the remaining 16 B-samples to be complete and the production of C-samples to begin in the second half of 2023.

07:42 EDT Lizhi's TIYA upgrades MY AI FRIEND with 'Animated Avatar' feature - LIZHI has launched a new expressive "Animated Avatar" feature for users' customized MY AI FRIEND chatbot with the latest update to its global social networking platform TIYA App. The new "Animated Avatar" feature for TIYA's MY AI FRIEND chatbot provides animated and expressive AI-generated faces to users' customized AI companions, further enhancing real-time conversations and fostering a deeper emotional connection between users and their AI companions.

07:39 EDT Incannex intends to redomicile to U.S., list all shares on Nasdaq - Incannex Healthcare announced its intention to redomicile from Australia to the United States via proposed schemes of arrangement between Incannex and its shareholders and Incannex and its optionholders. Implementation of the Schemes is subject to approval of IHL's shareholders and IHL's optionholders and other regulatory and court approvals. Incannex has already achieved registration of its ordinary shares from the US Securities and Exchange Commission. Since February 2022, Incannex's ordinary shares, in the form of American Depository Receipts, have been trading in the United States since gaining Nasdaq Global market listing status. Each ADR represents 25 ordinary shares of Incannex. Should the Schemes be approved by shareholders, all shareholders will be holders of shares of common stock of Incannex Healthcare Inc., the new parent company incorporated in Delaware, which will be listed on Nasdaq. Shares of common stock of US companies are tradable on all major share trading technology platforms in Australia, aiding trading liquidity. Furthermore, IHL will not delist from ASX until all relevant approvals from the SEC and Nasdaq to trade shares of common stock in Incannex Healthcare Inc. in the US have been obtained. Incannex's board of directors believes that becoming a U.S. company and trading only on NASDAQ will provide many and varied benefits to Incannex and its shareholders. The Company will have greater access to a more cognisant and receptive capital market of Incannex's value proposition, with comparison companies trading at far greater market valuations, and an ability to expand to a much broader investor base. To implement the re-domiciliation, Incannex has entered into a Scheme Implementation Deed with Incannex Healthcare, a new US company incorporated in Delaware. Following the implementation of the Schemes, Incannex US will become the ultimate parent company of the Incannex group of companies, with IHL becoming a wholly-owned subsidiary of Incannex US. Pursuant to the Share Scheme: holders of fully paid ordinary shares in Incannex will be entitled to receive one share of common stock in Incannex US for every 100 Incannex Shares held on the record date for the Share Scheme; and holders of Incannex ADRs will be entitled to receive one Incannex US Share for every four ADRs held in Incannex on the Share Scheme record date. Such a consolidation of share capital is considered appropriate following advice from numerous US investment banks concerning an appropriate pricing model for an ambitious and emerging biotechnology research and development company. To eliminate any confusion, it is worth noting that if the company were to apply the proposed 100-1 ratio, the estimated Nasdaq share price would currently be approximately US $8.00 per share. Furthermore any reorganisation of Capital does not affect the value of the company nor shareholder position. Pursuant to the Option Scheme, all options to acquire Incannex Shares on issue on the record date for the Option Scheme will be cancelled in consideration for the holders of those Incannex Options receiving one option to acquire a Incannex US Share for every 100 Incannex Options cancelled in accordance with the Option Scheme. If the Schemes are implemented, Incannex US Shares will be listed solely on Nasdaq. Incannex US will not seek to list on the Australian Securities Exchange on implementation of the Schemes. Accordingly, on implementation of the Schemes, IHL will cease to be ASX listed. The re-domiciliation is not expected to result in any material changes to Incannex's assets, management, operations or strategy, and is expected to be structured on a tax-neutral basis to Incannex and its shareholders. The implementation of the Schemes is subject to several customary conditions including the approval of Incannex shareholders, Incannex optionholders and the Federal Court of Australia, as well as other necessary regulatory approvals. Incannex shareholders and optionholders do not need to take any action at this time. A Scheme Booklet containing, among other things, more detailed information relating to the Schemes, reasons for the Board's recommendations, information on the Scheme meetings for the Share Scheme and the Option Scheme and the independent expert's report is expected to be mailed to Incannex shareholders and optionholders in August/September 2023. Incannex shareholders will be given the opportunity to vote on the Share Scheme and Incannex option holders will be given the opportunity to vote on the Option Scheme at the Scheme Meetings expected to be held in October 2023 and, subject to the conditions of the Schemes being satisfied, the Schemes are expected to be implemented in October 2023. These dates are indicative and subject to change.

07:36 EDT Auddia announces it has releases its exclusive offering faidrRadio to its app - Auddia announced that it has released its exclusive content offering faidrRadio to the Android version of its flagship mobile app, faidr. Podcasts were added to the product in May of this year. "We are excited that our Android users can begin listening to our faidrRadio programming alongside their favorite podcasts and commercial-free AM/FM stations," said Auddia's CEO Michael Lawless. "Since originally launching faidrRadio in our iOS product, we've seen it account for approximately 33% of all the plays in that app, and we're happy Android users now get to experience our exclusive Music Casts and Music Stations."

07:35 EDT Syneos Health appoints Bochniak as Chief Human Resources Officer - Syneos Health announced the appointment of Hillary Bochniak as Chief Human Resources Officer, effective July 10, 2023. Bochniak joins Syneos Health from Accenture where she spent nearly 30 years in human resources roles of increasing scope and responsibility. Most recently, she served as the Managing Director, Global HR Lead for Strategic Accounts and Sales, where she was a driving force behind Accenture's sales transformation.

07:33 EDT Camping World to acquire Sonny's RVs in Casper, Wyoming, no terms - Camping World Holdings announced that it is set to acquire Sonny's RVs in Casper, Wyoming. The transaction is anticipated to close in the fourth quarter of 2023 and will increase the Company's Wyoming location count to two. Marcus Lemonis, Chairman and CEO of Camping World commented, "

07:33 EDT Zai Lab announces China NMPA acceptance of efgartigimod alfa injection BLA - Zai Lab announced that China's National Medical Products Administration has accepted the Biologics License Application for efgartigimod alfa injection for the treatment of adult patients with generalized myasthenia gravis. The BLA submission is supported by positive results from the global Phase 3 ADAPT-SC study, demonstrating noninferior total IgG reduction from baseline at day 29 with SC administered efgartigimod compared to intravenous administered efgartigimod in adult patients with gMG. Patients treated with efgartigimod SC achieved mean total IgG reduction of 66.4% from baseline at day 29, compared to 62.2% reduction with efgartigimod IV. The safety profile for efgartigimod SC was also consistent with the ADAPT study. It was generally well-tolerated; the most frequent adverse event being injection site reactions, commonly observed with biologics administered subcutaneously. All ISRs were mild to moderate and resolved over time.

07:32 EDT MediWound announces results from its U.S. Phase I/II study of MW005 - MediWound announced positive data from its Phase I/II study to evaluate the safety and efficacy of MW005 in the treatment of low-risk Basal Cell Carcinoma, BCC. The data show MW005 to be safe and well-tolerated, with patients achieving complete clinical and histological clearance of their target lesions. The Phase I/II study is an open-label, multi-centered, randomized clinical trial designed to evaluate the safety and efficacy of MW005 in patients with BCC. All of the patients enrolled in the study had histologically confirmed superficial or nodular BCC. Fifteen patients were treated with MW005 and completed the study. Results showed MW005 to be safe and well-tolerated, with a high level of patient compliance. While the primary focus of the trial was on safety and tolerability, it is worth noting that based on clinical assessments, eleven out of fifteen patients achieved complete clearance of their BCCs; the majority of these patients also had histologically confirmed complete clearance. Data comprising clinical and histological outcomes, supported by extensive patient follow-up, will be featured at an upcoming scientific conference in 2023. Ofer Gonen, CEO of MediWound, said, "These data further validate the potential of MW005 as a significant advancement in cancer treatment. BCC affects two to three million individuals in the U.S. each year, and we believe MW005 may reduce the reliance on expensive and potentially disfiguring surgical procedures in certain cases, thereby improving patient experiences and outcomes."

07:15 EDT XP ends shareholders pact, Iupar Group loses right to nominate board members - XP Inc. announced the termination of its shareholders agreement executed between XP Control General Atlantic Bermuda LP, Itausa S.A. Sao Carlos Investimentos , Sao Marcos Investimentos ITB Holding and Itau Unibanco Holding , originally expected to continue until October, 2026. This termination was agreed to between the shareholders and strengthens XP Inc.'s corporate governance practices and the composition of its board of directors. As a result of the termination, 1. Iupar Group will no longer have the right to nominate members to our board, but together with Itau, they will still be required to adhere to the registration rights when selling their shares in the market. 2. GA will maintain its right to nominate one board member as long as it maintains a minimum of 2% ownership in XP Inc.; and 3. XP Inc.'s board will be reduced to 9 members to improve its effectiveness.

07:13 EDT Mobilicom secures commercial scale purchase order for SkyHopper PRO systems - Mobilicom (MOB) announced a commercial scale purchase order from one of its Tier-1 customers, Teledyne-FLIR (TDY), for 120 of Mobilicom's SkyHopper PRO datalink systems. Teledyne-FLIR selected Mobilicom's SkyHopper PRO as an essential component in its new small-sized drone platform. Having completed the design, development, integration, testing, and validation of this drone platform, Teledyne-FLIR has moved it into the commercialization phase with federal agencies and customers across the U.S. This latest and largest purchase order to date from Teledyne-FLIR is for SkyHopper PRO systems to be integrated into small-sized drones manufactured for the U.S. Department of Defense. Delivery of the SkyHopper PRO systems to Teledyne-FLIR under this purchase order is expected during 2023.

07:11 EDT DualityBio eligible for $1.3B in BeiGen pact for ADC therapy for tumors - BeiGen and DualityBio, a next-generation ADC company, announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. "With one of the industry's leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynamic and growing pipeline in solid tumors," said Lai Wang, Ph.D., Global Head of R&D at BeiGene. "Through this strategic partnership with DualityBio, we are well positioned to advance this asset globally alongside our initial internally discovered ADC assets with our end-to-end ADC manufacturing capabilities." "Duality is dedicated to becoming a leading next-generation ADC company, and the assets built upon our DITAC platform show encouraging efficacy and safety in preclinical as well as global clinical studies," said John Zhu, Ph.D., CEO at DualityBio. "We are excited to partner with BeiGene to accelerate the development of this asset. In combining the strengths of BeiGene and Duality, we believe more breakthrough ADC medicines will be brought to patients worldwide." Under the terms of the agreement, DualityBio will receive an upfront payment, and will be eligible for a payment contingent upon BeiGene exercising its option and additional payments based upon the achievement of certain development, regulatory, and commercial milestones, totaling up to $1.3B, in addition to tiered royalties. Upon exercising its option, BeiGene will hold global clinical, manufacturing, and commercial rights while DualityBio will perform all research activities through IND-enabling studies and support future IND filings by BeiGene.

07:11 EDT Societal CDMO selected by Spinnaker Biosciences to provide CDMO services - Societal CDMO announced that it has been selected by Spinnaker Biosciences to execute CDMO services in support of the company's clinical development of a novel therapeutic candidate. The activities to be conducted under the agreement include analytical method transfer and qualification, aseptic process development, manufacture of a prototype batch of the therapeutic, cGMP filling of the resultant sterile powder into vials, and stability testing of the therapeutic candidate to be used in a planned Phase 1/2 study. "Our new agreement with Spinnaker is an exciting opportunity for the Societal CDMO team to showcase its range of expertise across a number of offerings designed to support innovative drug developers as they work to advance novel therapeutic candidates into the clinic. We are well suited to carry out this work which involves several complexities, including aseptic filling of the final product," said David Enloe, chief executive officer of Societal CDMO. "We are excited to add Spinnaker to our growing list of customers and pleased that the company has entrusted us to carry out these important aseptic process development and manufacturing activities on its behalf."

07:09 EDT Clearside announces TGA of Australia accepted Arctic Vision's NDA for Arcatus - Clearside Biomedical announced that the Therapeutic Goods Administration, TGA, of Australia has formally accepted Arctic Vision's new drug application, NDA, for suprachoroidal use of Arcatus for the treatment of Uveitic Macular Edema. Arctic Vision is a specialty ophthalmology company based in China that has the exclusive license for the commercialization and development of XIPERE. "Acceptance of the NDA in Australia is additional validation of suprachoroidal administration as an innovative, recognized form of ophthalmic drug delivery and another step towards the global commercialization of XIPERE," said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside. "With approval in the U.S., regulatory review ongoing in Australia, and plans to gradually submit applications in more countries in its territories, our partner Arctic Vision continues to expand access for patients to the only product approved for the treatment of macular edema associated with uveitis."

07:08 EDT Koru Medical submits FREEDOM60 510(k) premarket notification submission to FDA - Koru Medical announced that it has submitted a 510(k) premarket notification submission to the FDA for the use of its FREEDOM60 Infusion System with Hizentra 50 mL prefilled syringes.

07:08 EDT Genelux announces publication of Phase 1 trial results of Olvi-Vec - Genelux Corporation announced the publication in Frontiers in Immunology of positive results from a Phase 1 trial exploring intrapleural delivered Olvi-Vec in patients with malignant pleural effusion due to either MPM or metastatic disease. The study was completed at Memorial Sloan Kettering Cancer Center. This Phase 1 clinical trial enrolled eighteen MPE patients, who underwent a dose escalating method of intrapleural administration of Olvi-Vec following drainage of MPE. The primary objective of this trial was to determine a recommended dose. The secondary objectives were to assess feasibility, safety and tolerability; evaluate viral presence in the tumor and serum as well as viral shedding in pleural fluid, sputum, and urine; and evaluate anti-vaccinia virus immune response. Key Findings: Treatment with Olvi-Vec at the dose of 1x107 plaque-forming units to 6x109 PFU was feasible and safe, with no treatment-associated mortalities or dose-limiting toxicities. Olvi-Vec was detectable in tumor cells 2-5 days post-treatment, and treatment was associated with a decrease in tumor cell density and an increase in immune cell density as assessed by a pathologist blinded to the clinical observations. When matched tumor specimens were compared, tumor cell density score decreased from pre-treatment to post-treatment in all patients. Immune cell density score increased from pre-treatment to post-treatment in 3 of 4 patients. Gene expression analysis of pre- and post-treatment tumor specimens, using nCounter immune cell type scoring module, revealed increased scores for CD45+, Th1+, Tregs, CD8+, exhausted CD8+, NK+, cytotoxic cells, dendritic cells, macrophage, and neutrophil immune cell populations in post-treatment tumor specimens compared to pre-treatment specimens. Among all patients, median OS was 19.5 months. The median OS among patients who had MPM was 22 months. One patient with epithelioid MPM is alive at time of manuscript publication; 87 months after Olvi-Vec treatment, this patient received other treatments that are standard of care for patients with MPM. The maximum tolerated dose was not reached. As a result, the primary objective of establishing a recommended dose was not reached.

07:07 EDT Exscientia enrolls first patient in ELUCIDATE study - Exscientia announced that it has enrolled the first patient in its Phase 1/2 "ELUCIDATE" study evaluating GTAEXS617, Exscientia's precision-designed CDK7 inhibitor, for the treatment of advanced solid tumours. The clinical trial will evaluate the safety, efficacy and pharmacokinetics of '617 across multiple ascending doses in patients with advanced solid tumours including head and neck cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, HR+/HER2- breast carcinoma and ovarian cancer. '617 is a novel CDK7 inhibitor that has been designed by Exscientia in collaboration with GT Apeiron for high potency, selectivity, oral bioavailability and safety.

07:06 EDT Canadian Solar rebrands CSI Solar energy storage division to e-STORAGE - Canadian Solar and its majority-owned subsidiary, CSI Solar, announced the re-branding of e-STORAGE, CSI Solar's utility-scale battery energy storage subsidiary and platform. With e-STORAGE, Canadian Solar will accelerate its growth in the global energy storage market and operate as a distinct business unit, under CSI Solar. Previously, e-STORAGE operated as CSI Energy Storage. e-STORAGE launches with nearly 26 GWh of energy storage projects in its total pipeline and over $1.7B of contracted revenues as of July 2023, up from $1B in January 2023. This provides significant growth visibility for e-STORAGE over a multi-year period.

07:05 EDT GT Apeiron announces enrollment of first patient in Phase 1/2 ELUCIDATE study - GT Apeiron announced the enrollment of the first patient in the Phase 1/2 "ELUCIDATE" study which is designed to evaluate GTAEXS617 for the treatment of advanced solid tumors. Developed in collaboration with its strategic partner, Exscientia, GTAEXS617 is a highly selective, small molecule, non-covalent inhibitor of cyclin-dependent kinase 7. "The initiation of the ELUCIDATE study represents a significant milestone in our company's development and is the first drug candidate from our partnership with Exscientia to enter clinical studies," said Mingxi Li, Ph.D., chief executive officer of GT Apeiron. "GTAEXS617 is a product of our collaboration that uses AI-driven precision design to create a potentially best-in-class therapy and provide a new therapeutic option for patients with these difficult to treat cancers."

07:04 EDT EnCore Energy reports 19.9% ownership of Nuclear Fuels - enCore Energy announced that the company has received 9,263,800 shares of Nuclear Fuels, formerly Uravan Minerals, in exchange for shares of a private BC company which held uranium projects in Wyoming and Arizona. Immediately prior to the acquisition, enCore held 64,000 post-consolidated common shares of Nuclear Fuels. Following the business transaction completion, enCore holds a total of 9,327,800 shares representing approximately 19.9% of the issued and outstanding common shares of Nuclear Fuels.

07:03 EDT Marker Therapeutics granted Orphan Drug Designation from EMA for MT-401 - Marker Therapeutics announced that zedenoleucel, its multi-tumor-associated antigen-specific T cell product candidate, MT-401, was granted Orphan Drug Designation by the Committee for Orphan Medicinal Products of the European Medicines Agency for the treatment of patients with acute myeloid leukemia. AML is a life-threatening and chronically debilitating disease that is rapidly progressive and fatal if untreated. Relapse rates after initial treatment are high, and the next step for eligible patients is an allogeneic hematopoietic stem cell transplant. Unfortunately, AML relapse after HSCT is frequent and outcomes are dismal. Patients who relapse after HSCT have an estimated median survival of less than one year, highlighting the urgent need for new therapies. MT-401 utilizes a novel non-genetically modified approach that recognizes multiple antigens expressed on tumor cells, thereby designed to minimize tumor escape. MT-401 is currently being studied in a Phase 2 clinical trial for the treatment of relapsed AML following allogeneic HSCT, and was designed to specifically target four different antigens that are upregulated in AML but have limited expression on normal cells.

07:02 EDT Tango Therapeutics announces first patient dosed in Phase 1/2 trial of TNG462 - Tango Therapeutics announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patients with MTAP-deleted solid tumors. TNG462 is a potentially best-in-class MTA-cooperative PRMT5 inhibitor previously granted Fast Track designation by the U.S. Food and Drug Administration. The TNG462 phase 1/2 clinical trial will evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of TNG462 in solid tumors with MTAP deletions. "Dosing the first patient with our next-generation MTA-cooperative PRMT5 inhibitor, TNG462, demonstrates our deep commitment to developing transformative treatments for patients with MTAP-deleted cancers. MTAP deletions occur in 10-15 percent of solid tumors, including many with limited treatment options, and there currently are no FDA-approved treatments specifically for cancers with MTAP deletion," said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics.

07:01 EDT Fulcrum Therapeutics signs exclusive license agreement with CAMP4 Therapeutics - Fulcrum Therapeutics announced that it has entered into a worldwide, exclusive license agreement with CAMP4 Therapeutics, whereby Fulcrum will advance the discovery, development, and commercialization of novel therapeutic agents against an undisclosed target for the potential treatment of Diamond-Blackfan Anemia, DBA. Under the terms of the agreement, Fulcrum has been granted an exclusive, worldwide license to intellectual property arising from CAMP4's DBA program, including the right to research, develop, manufacture, and commercialize investigational compounds against an undisclosed target. In exchange, CAMP4 Therapeutics will receive an undisclosed upfront payment and up to $70 million in additional payments, upon the achievement of certain development, regulatory, and commercial milestones. Fulcrum will assume sole responsibility for research, development, manufacturing and commercialization costs and activities, and will pay tiered royalties on future commercial sales.

06:50 EDT International Game issues statement regarding passing of Fabio Cairoli - International Game released the following statement regarding the passing of Fabio Cairoli, IGT CEO Global Lottery: "IGT announced today with great sadness that Fabio Cairoli, IGT CEO of Global Lottery, has suddenly passed away. Fabio was an outstanding executive. He was distinguished by his passion, drive, sincerity, and commitment to results and innovation. His leadership of the Global Lottery Sales and Operations, Italy Lottery Operations, Global Lottery Product and Sales Development, and Global Lottery Technology and Support functions was unparalleled. While these operations remain in very capable and experienced hands, we recognize that many in the lottery industry also held personal relationships with Fabio, and that he was a greatly respected friend within and beyond the industry," said Marco Sala, IGT Executive Chair. "At this time, IGT extends its deepest condolences to Fabio Cairoli's family, as we dedicate our efforts to supporting their needs during this difficult time."

06:38 EDT Vermilion Energy announces TSX approval of NCIB - Vermilion Energy announced that the Toronto Stock Exchange has approved the notice of Vermilion's intention to commence a normal course issuer bid, or NCIB, through the facilities of the Toronto Stock Exchange, New York Stock Exchange and other alternative trading platforms in Canada and USA. The NCIB allows Vermilion to purchase up to 16,308,587 common shares, representing approximately 10% of its public float as at June 28, over a twelve month period commencing on July 12. The NCIB will expire no later than July 11, 2024. The total number of common shares Vermilion is permitted to purchase on the TSX is subject to a daily purchase limit of 297,362 common shares, representing 25% of the average daily trading volume of 1,189,450 common shares on the TSX calculated for the six-month period ended June 30, 2023; however, Vermilion may make one block purchase per calendar week which exceeds the daily repurchase restrictions. Any common shares that are purchased under the NCIB will be cancelled upon their purchase by Vermilion.

06:04 EDT ChipMOS reports Q2 revenue $174.8M, up 18.2% - ChipMOS reported its unaudited consolidated revenue for the month of June and for the second quarter ended June 30. All U.S. dollar figures cited in this press release are based on the exchange rate of NT$31.14 to $1.00 as of June 30. Revenue for the second quarter of 2023 was $174.8M, representing an increase of 18.2% from the first quarter and a decrease of 20.5% from the second quarter of 2022. The company noted the above seasonally strong second quarter of 2023 revenue reflects higher demand of LCD drivers across its core business and automotive markets, along with a continued improvement in loading levels of high end test platform. Revenue for the month of June was $57.4M, representing a slight decrease of 2.5% from May 2023, and a decrease of 15.3% from June 2022.

06:02 EDT Matterport, Equinox to deliver digital twin platform to Middle East and Africa - Matterport announced that it is partnering with Equinox Technologies, a distributor of global technologies and Managed Security Services, to offer Matterport's digital twin platform to Government, Enterprise and SMB customers out of its offices in the United Arab Emirates, India, Oman, Saudi Arabia, and South Africa.

05:32 EDT Union Pacific, SMART-TD reach tentative pact to provide eight paid sick days - Union Pacific Railroad and the International Association of Sheet Metal, Air, Rail and Transportation Workers, or SMART-TD, reached a tentative agreement to provide up to eight paid sick leave days to around 5,900 railroad employees.

05:19 EDT Elbit Systems awarded $114M contract by Asian-Pacific country to supply two LRPA - Elbit Systems announced that it was awarded a contract worth approximately $114M with an Asian-Pacific country to supply two long-range patrol aircraft, or LRPA, equipped with an advanced and comprehensive mission suite. The contract will be carried out over a period of five years. The two LRPA aircraft will be based on new ATR 72-600 and Elbit Systems will integrate in each aircraft a mission suite that includes a Mission Management System, Electro-Optics, Radar, SIGINT, Communication and more.

05:14 EDT Nasdaq, B3 enter pact to develop new clearing platform for Brazil stock exchange - B3 and Nasdaq have announced a partnership to develop a new clearing platform for the Brazilian stock exchange, responsible for the clearing, settlement, and management of counterparty risk associated with financial market transactions. The multi-year work schedule between B3 and Nasdaq will see close collaboration between engineering teams, drawing on Nasdaq's expertise providing real-time clearing solutions to over 20 central counterparty clearing houses worldwide.